Search results for "cardiovascular."

showing 10 items of 8644 documents

Thrombolytic therapy for submassive pulmonary embolism.

2012

Approximately 10% of all patients with acute pulmonary embolism (PE) die within the first three months after diagnosis. However, PE is not universally life-threatening, but covers a wide spectrum of clinical severity and death risk. Thrombolytic treatment is indicated patients with acute massive PE who are at high risk for early death, i.e. those patients who present with arterial hypotension and shock. On the other hand, low molecular-weight heparin or fondaparinux is adequate treatment for most normotensive patients with PE. Recombinant tissue plasminogen activator, given as 100 mg infusion over 2 h, is the treatment of choice for patients with PE, although older regimens using urokinase …

medicine.medical_specialtymedicine.medical_treatmentStreptokinaseVentricular Dysfunction RightClinical Biochemistry030204 cardiovascular system & hematologyFondaparinuxlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialFibrinolytic AgentslawPolysaccharidesRisk FactorsInternal medicinemedicineHumansStreptokinaseThrombolytic Therapy030212 general & internal medicineIntensive care medicineUrokinaseClinical Trials as Topicbusiness.industryHeparinThrombolysisHeparin Low-Molecular-Weightmedicine.diseaseUrokinase-Type Plasminogen ActivatorTroponin3. Good healthPulmonary embolismRadiographyOncologyFondaparinuxTissue Plasminogen ActivatorAcute DiseaseCardiologybusinessPulmonary EmbolismBiomarkersmedicine.drugCohort studyBest practiceresearch. Clinical haematology
researchProduct

Transcatheter embolization of the kidney with butyl-2-cyanoacrylate: Experimental and clinical results

1978

The technique and efficacy of therapeutic catheter embolization of the kidney with butyl-2-cyanoacrylate (Histoacryl) were studied in 80 rabbits (including control groups) and in 10 dogs. A mixture of butyl-2-cyanoacrylate, 50% glucose, and tantalum powder was used for the embolization. Complete and permanent vascular occlusion was found in nearly all cases. The main complication observed was a reflux of embolizing material into the lumbar arteries, which occurred in seven rabbits. Clinically, therapeutic embolization was performed in six patients with hypernephroma. The indication for embolization in these patients, as well as in two others with iatrogenic lesions, was pronounced hematuria…

medicine.medical_specialtymedicine.medical_treatmentTantalumAdenocarcinomaVascular occlusionCatheterizationlaw.inventionDogsRenal Arterylawmedicine.arterymedicineAnimalsHumansRadiology Nuclear Medicine and imagingCyanoacrylatesEmbolizationHematuriaKidneybusiness.industryLumbosacral RegionRefluxEnbucrilateEmbolization TherapeuticKidney NeoplasmsSurgeryRadiographyCathetermedicine.anatomical_structureCyanoacrylateRabbitsRadiologymedicine.symptomCardiology and Cardiovascular MedicineComplicationbusinessLumbar arteriesCardiovascular Radiology
researchProduct

An International, Multicenter Retrospective Observational Study to Assess Technical Success and Clinical Outcomes of Patients Treated with an Endovas…

2022

Introduction: Type III endoleaks post-endovascular aortic aneurysm repair (EVAR) warrant treatment because they increase pressure within the aneurysm sac leading to increased rupture risk. The treatment may be difficult with regular endovascular devices. Endovascular aneurysm sealing (EVAS) might provide a treatment option for type III endoleaks, especially if located near the flow divider. This study aims to analyze clinical outcomes of EVAS for type III endoleaks after EVAR. Methods: This is an international, retrospective, observational cohort study including data from 8 European institutions. Results: A total of 20 patients were identified of which 80% had a type IIIb endoleak and the r…

medicine.medical_specialtymedicine.medical_treatmentTechnical successClinical Investigationsendoleak030204 cardiovascular system & hematologyProsthesis DesignEndovascular aneurysm repair030218 nuclear medicine & medical imagingendovascular aneurysm repair03 medical and health sciencesBlood Vessel Prosthesis Implantation0302 clinical medicineAneurysmabdominal aortic aneurysmRisk FactorsmedicineMANAGEMENTHumansabdominal aortic aneurysm; aneurysm; endoleak; endovascular aneurysm repair; reinterventionRadiology Nuclear Medicine and imagingRupture riskcardiovascular diseasesRetrospective StudiesreinterventionREPAIRAortic aneurysm repairABDOMINAL AORTIC-ANEURYSMSIncrease pressurebusiness.industryEndovascular ProceduresRetrospective cohort studymedicine.diseaseAbdominal aortic aneurysmSurgeryBlood Vessel ProsthesisTreatment Outcomecardiovascular systemaneurysmREPORTING STANDARDSSurgeryStentsCardiology and Cardiovascular MedicinebusinessAortic Aneurysm AbdominalJournal of Endovascular Therapy
researchProduct

Ultrasound-induced blood clot dissolution without a thrombolytic drug is more effective with lower frequencies.

2004

<i>Background and Purpose:</i> Therapeutic ultrasound as stand-alone therapy or in combination with rt-PA has proven to be an effective measure for recanalisation of acute vessel occlusion in different in vitro and in vivo studies. Uncertainty still exists concerning the optimal frequency and intensity with regard to the thrombolytic efficacy of ultrasound. The purpose of this study was a direct comparison of different ultrasound frequencies, when otherwise using identical measurement settings and parameters. <i>Methods:</i> Ultrasound-induced dissolution of fresh human blood clots was studied in a flow system using low-frequency continuous wave ultrasound of 20, 40 …

medicine.medical_specialtymedicine.medical_treatmentVessel occlusionThrombolytic drugInternal medicinemedicineHumansThrombolytic TherapyUltrasonicsStrokeBlood CoagulationUltrasonographyTherapeutic ultrasoundbusiness.industryUltrasoundAnticoagulantsThrombolysisFrequency dependencemedicine.diseaseRecombinant ProteinsSurgeryBloodNeurologyCalibrationCardiologyNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessCerebrovascular diseases (Basel, Switzerland)
researchProduct

Diuretic Strategies in Acute Heart Failure and Renal Dysfunction: Conventional vs Carbohydrate Antigen 125-guided Strategy. Clinical Trial Design

2017

Abstract Introduction and objectives The optimal treatment of patients with acute heart failure (AHF) and cardiorenal syndrome type 1 (CRS-1) is far from being well-defined. Arterial hypoperfusion in concert with venous congestion plays a crucial role in the pathophysiology of CRS-I. Plasma carbohydrate antigen 125 (CA125) has emerged as a surrogate of fluid overload in AHF. The aim of this study was to evaluate the clinical usefulness of CA125 for tailoring the intensity of diuretic therapy in patients with CRS-1. Methods Multicenter, open-label, parallel clinical trial, in which patients with AHF and serum creatinine ≥ 1.4 mg/dL on admission will be randomized to: a) standard diuretic str…

medicine.medical_specialtymedicine.medical_treatmentWater-Electrolyte ImbalanceRenal functionCardiorenal syndrome030204 cardiovascular system & hematologyPatient Care Planning03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFurosemideInternal medicineHumansMedicine030212 general & internal medicineDiureticsIntensive care medicineHeart FailureCreatinineCardio-Renal Syndromebusiness.industryClinical study designChlorthalidoneMembrane ProteinsGeneral Medicinemedicine.diseasePathophysiologyAcetazolamideClinical trialchemistryCA-125 AntigenCreatinineHeart failureAcute DiseaseCardiologyDiureticbusinessRevista Española de Cardiología (English Edition)
researchProduct

Identification of Flow-Limiting Coronary Stenosis With PCS: A New Cost-Effective Index Derived From the Product of Corrected TIMI Frame Count and Per…

2021

Background: Identifying functional coronary stenosis with simple and cost-effective methods during invasive coronary angiography is still challenging. Corrected TIMI frame count (CTFC) is considered to be the frame count velocity of coronary blood flow. We aimed to propose a simple and cost-effective index based on CTFC and percent diameter stenosis (DS) to identify flow-limiting coronary stenosis. For this, a new index was put forward as the product of CTFC and DS (PCS). PCS can be regarded as the loss of coronary blood flow due to diameter stenosis.Methods: DS, CTFC, PCS, and Fractional flow reserve (FFR) of 111 vessels in 84 patients with suspected coronary heart disease were measured. F…

medicine.medical_specialtymedicine.medical_treatmentYouden's J statisticFractional flow reserveCardiovascular MedicinePercent Diameter StenosisCoronary artery diseaseInternal medicinemedicineDiseases of the circulatory (Cardiovascular) systemfractional flow reserveOriginal Researchbusiness.industrypercutaneous coronary interventionPercutaneous coronary interventioncorrected TIMI frame countBlood flowmedicine.diseaseflow-limiting coronary stenosisStenosisRC666-701CardiologyCardiology and Cardiovascular MedicinebusinessTIMIcoronary artery diseaseFrontiers in Cardiovascular Medicine
researchProduct

Multivessel Intervention in Myocardial Infarction with Cardiogenic Shock: CULPRIT-SHOCK Trial Outcomes in the PL-ACS Registry

2021

Background: The aim of the study was a comparison of culprit-lesion-only (CL-PCI) with the multivessel percutaneous coronary intervention (MV-PCI) in terms of 30-day and 12-month mortality in a national registry. Methods: Patients from the PL-ACS registry with MI and CS were analyzed. Patients meeting the criteria of the CULPRIT-SHOCK trial were divided into two groups: CL-PCI and MV-PCI groups. Results: Of the 3265 patients in the PL-ACS registry with MI complicated by CS, the criteria of the CULPRIT-SHOCK trial were met by 2084 patients (63.8%). The CL-PCI was performed in 883 patients, and MV-PCI was performed in 1045 patients. After the propensity score matching analysis, 617 well-match…

medicine.medical_specialtymedicine.medical_treatmentacute myocardial infarction030204 cardiovascular system & hematologyRevascularizationacute myocardial infarction; cardiogenic shock; percutaneous coronary interventionCulpritArticle03 medical and health sciences0302 clinical medicineInternal medicineMedicinecardiovascular diseases030212 general & internal medicineMyocardial infarctionbusiness.industryCardiogenic shockcardiogenic shockpercutaneous coronary interventionRPercutaneous coronary interventionGeneral Medicinemedicine.diseasesurgical procedures operativemedicine.anatomical_structureShock (circulatory)Propensity score matchingMedicinemedicine.symptombusinessArteryJournal of Clinical Medicine
researchProduct

Cholesterol accumulation is increased in macrophages of phospholipid transfer protein-deficient mice: normalization by dietary alpha-tocopherol suppl…

2007

Objective— Phospholipid transfer protein (PLTP) is a multifunctional, extracellular lipid transport protein that plays a major role in lipoprotein metabolism and atherosclerosis. Recent in vivo studies suggested that unlike systemic PLTP, macrophage-derived PLTP would be antiatherogenic. The present study aimed at characterizing the atheroprotective properties of macrophage-derived PLTP. Methods and Results— Peritoneal macrophages were isolated from PLTP-deficient and wild-type mice and their biochemical characteristics were compared. It is shown that macrophages isolated from PLTP-deficient mice have increased basal cholesterol content and accumulate more cholesterol in the presence of LD…

medicine.medical_specialtymedicine.medical_treatmentalpha-TocopherolOxidative phosphorylationBiologychemistry.chemical_compoundMiceIn vivoPhospholipid transfer proteinInternal medicineMalondialdehydeExtracellularmedicineAnimalsTocopherolPhospholipid Transfer ProteinsMice KnockoutCholesterolVitamin EVitaminsLipoproteins LDLEndocrinologyCholesterolchemistryBiochemistryDietary SupplementsMacrophages Peritoneallipids (amino acids peptides and proteins)Cardiology and Cardiovascular Medicinealpha-TocopherolArteriosclerosis, thrombosis, and vascular biology
researchProduct

Long-Term Outcome with New Generation Prostheses in Patients Undergoing Transcatheter Aortic Valve Replacement

2021

The aim of this study was to compare patients with transcatheter aortic valve replacement (TAVR) receiving new generation prostheses SAPIEN 3 (S3, Edwards Lifesc.) and Evolut R (ER, Medtronic Inc.) in terms of periprocedural and long-term outcome. Our retrospective, single-center analysis included 359 consecutive patients with severe aortic stenosis who underwent TAVR with S3 or ER from 2014–2016 (mean age 82 ± 7 years, 47% male, mean EuroSCORE II 8.0 ± 8%, mean follow-up 3.8 years). Device Success was equal (S3 93.0% vs. ER 92.4%, p = 0.812). We report a 30-day mortality of 2.8% in the S3 group, and 2.1% in the ER group (p = 0.674). There was no difference in stroke, conversion to open sur…

medicine.medical_specialtymedicine.medical_treatmentaortic valve stenosis030204 cardiovascular system & hematologyTAVRnew-generation trans-catheter heart valvesProsthesisArticle03 medical and health sciences0302 clinical medicineValve replacementInternal medicinemedicine030212 general & internal medicineMyocardial infarctionStrokeEjection fractionbusiness.industryRGeneral Medicinemedicine.diseaseStenosisAortic valve stenosisCardiologyMedicineImplantbusinesslong-term outcomesJournal of Clinical Medicine
researchProduct

Endovascular Repair of Contained Abdominal Aortic Aneurysm Rupture Using a Bilateral D-Shaped Stent System

2017

To report the first case of the treatment of a contained aortic aneurysm rupture using a bilateral D-shaped endovascular stent graft system.

medicine.medical_specialtymedicine.medical_treatmentcontained ruptured aneurysm030204 cardiovascular system & hematologySystem a03 medical and health sciences0302 clinical medicineAneurysmAortic aneurysm rupturemedicineEVARcardiovascular diseasesAAAbusiness.industryStent030229 sport sciencesGeneral Medicineequipment and suppliesmedicine.diseaseAbdominal aortic aneurysmSurgerysurgical procedures operativeaneurysmcardiovascular systemSurgeryCardiology and Cardiovascular MedicinebusinessVascular and Endovascular Surgery
researchProduct